IRVINE, Calif.--(BUSINESS WIRE)--Spectrum Pharmaceuticals, Inc., (Nasdaq:SPPI) announced that preclinical data on SPI-1620 were presented via poster presentations at the 6th International Symposium on Targeted Anticancer Therapies, in Bethesda, Maryland. SPI-1620, a highly selective endothelin-B agonist, is being developed as an adjunct to cancer therapy.
